phrykt

Abeona Therapeutics Inc. (ABEO): who owns it and who trades it

As of Nov 16, 2026, ABEO insiders reported 37 open-market sales worth $3.5M and 1 purchase worth $34.3K in the last 12 months, with 19% of the sale value made under pre-set 10b5-1 plans. The largest seller was Vishwas Seshadri (CEO), with $1.5M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Abeona Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ABEO

127 funds and institutions reported ABEO shares worth $276M at the end of Q2 2026, about 78% of the company. The largest holder is Nantahala Capital Management, LLC with 18.0%.

Funds and institutions (13F) 78%Everyone else 22%

10 largest owners, by share of the company

Nantahala Capital Management, LLC18.0%
BlackRock, Inc.5.9%
Cable Car Capital, LP5.3%
AIGH Capital Management LLC5.2%
Vanguard Capital Management LLC3.9%
OneDigital Investment Advisors LLC2.9%
AWM Investment Company, Inc.2.6%
Geode Capital Management, LLC2.2%
Kennedy Capital Management LLC2.2%
Goldman Sachs Group Inc2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC10.27M18.01%$63.5M+105%
BlackRock, Inc.3.35M5.88%$20.7M+5%
Cable Car Capital, LP3.01M5.27%$18.6MNo change
AIGH Capital Management LLC2.99M5.24%$18.5M-4%
Vanguard Capital Management LLC2.21M3.88%$13.7M+2%
OneDigital Investment Advisors LLC1.65M2.90%$10.2M–
AWM Investment Company, Inc.1.49M2.61%$9.2M+85%
Geode Capital Management, LLC1.26M2.21%$7.8M+4%
Kennedy Capital Management LLC1.24M2.17%$7.7M-2%
Goldman Sachs Group Inc1.22M2.15%$7.6M+8%
State Street Corp1.04M1.82%$6.4M+9%
Propel Bio Management, LLC983,0701.72%$6.1M-26%
Nan Fung Trinity (hk) Ltd956,7701.68%$5.9MNo change
Diametric Capital, LP755,0211.32%$4.7M+23%
J. Goldman & Co LP678,1731.19%$4.2M+6%
Silverarc Capital Management, LLC610,4071.07%$3.8M-6%
Rubric Capital Management LP608,7711.07%$3.8M–
Stonepine Capital Management, LLC557,2840.98%$3.4M-25%
Northern Trust Corp552,6300.97%$3.4M+27%
Citigroup Inc548,3000.96%$3.4M+5%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ABEO insiders reported $34.3K of open-market purchases and $3.5M of sales. 19% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$34.3K
1 trades, 1 people
Sales, 12 months
$3.5M
37 trades, 9 people
Sales under a 10b5-1 plan
19%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$847K$847KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Faith L. CharlesDirectorPurchase15,000$2.29$34.3KForm 4
Sep 29, 2026Vishwas SeshadriCEOSale19,608$5.16$101KForm 4
Sep 29, 2026Joseph Walter VazzanoCFOSale9,191$5.16$47.4KForm 4
Sep 29, 2026Brendan M. O'MalleyVice presidentSale6,727$5.16$34.7KForm 4
Sep 29, 2026Madhav VasanthavadaChief Commercial OfficerSale4,902$5.16$25.3KForm 4
Sep 1, 2026Mark AlvinoDirectorSale15,000$5.86$87.9KForm 4
Jul 21, 2026Joseph Walter VazzanoCFOSale1,478$6.53$9.7KForm 4
Jul 9, 2026Joseph Walter VazzanoCFOSale24,880$6.96$173KForm 4
Jul 9, 2026Vishwas SeshadriCEOSale67,971$6.96$473KForm 4
Jul 9, 2026Brendan M. O'MalleyVice presidentSale12,050$6.96$83.9KForm 4
Jul 9, 2026Madhav VasanthavadaChief Commercial OfficerSale12,606$6.96$87.7KForm 4
Jun 30, 2026Leila AllandDirectorSale11,000$5.92$65.1KForm 4
Jun 15, 2026Christine Berni SilversteinDirectorSale18,160$5.71$104KForm 4
Jun 9, 2026Joseph Walter VazzanoCFOSale plan13,421$5.30$71.1KForm 4
Jun 9, 2026Brendan M. O'MalleyVice presidentSale6,305$5.30$33.4KForm 4
Jun 9, 2026Joseph Walter VazzanoCFOSale plan25,646$5.39$138KForm 4
Jun 9, 2026Vishwas SeshadriCEOSale31,916$5.30$169KForm 4
Jun 9, 2026Madhav VasanthavadaChief Commercial OfficerSale5,450$5.30$28.9KForm 4
Jun 8, 2026Vishwas SeshadriCEOSale24,428$5.43$133KForm 4
Jun 8, 2026Joseph Walter VazzanoCFOSale plan10,271$5.43$55.8KForm 4
Jun 8, 2026Brendan M. O'MalleyVice presidentSale4,826$5.43$26.2KForm 4
Jun 8, 2026Madhav VasanthavadaChief Commercial OfficerSale4,170$5.43$22.6KForm 4
May 22, 2026Mark AlvinoDirectorSale6,500$5.46$35.5KForm 4
May 15, 2026Eric CrombezDirectorSale plan26,143$5.53$145KForm 4
May 11, 2026Madhav VasanthavadaChief Commercial OfficerSale5,548$5.96$33.1KForm 4
Mar 31, 2026Vishwas SeshadriCEOSale plan29,985$4.38$131KForm 4
Mar 16, 2026Joseph Walter VazzanoCFOSale785$4.76$3.7KForm 4
Feb 2, 2026Christine Berni SilversteinDirectorSale20,070$5.09$102KForm 4
Feb 2, 2026Donald A. WuchterlDirectorSale14,814$5.09$75.4KForm 4
Feb 2, 2026Eric CrombezDirectorSale16,284$5.09$82.9KForm 4
Feb 2, 2026Leila AllandDirectorSale18,065$5.09$92KForm 4
Feb 2, 2026Mark AlvinoDirectorSale2,000$5.09$10.2KForm 4
Jan 22, 2026Madhav VasanthavadaChief Commercial OfficerSale12,610$5.29$66.7KForm 4
Jan 22, 2026Joseph Walter VazzanoCFOSale18,666$5.33$99.5KForm 4
Jan 22, 2026Vishwas SeshadriCEOSale69,832$5.33$372KForm 4
Jan 22, 2026Brendan M. O'MalleyVice presidentSale13,578$5.33$72.4KForm 4
Jan 21, 2026Mark AlvinoDirectorSale13,500$5.23$70.6KForm 4
Dec 29, 2025Vishwas SeshadriCEOSale plan25,000$5.31$133KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Vishwas SeshadriChief Executive Officer, Director–$1.5MSep 29, 2026
Joseph Walter VazzanoChief Financial Officer–$599KSep 29, 2026
Madhav VasanthavadaChief Commercial Officer–$264KSep 29, 2026
Brendan M. O'MalleySVP, Chief Legal Officer–$251KSep 29, 2026
Eric CrombezDirector–$227KMay 15, 2026
Christine Berni SilversteinDirector–$206KJun 15, 2026
Mark AlvinoDirector–$204KSep 1, 2026
Leila AllandDirector–$157KJun 30, 2026
Donald A. WuchterlDirector–$75.4KFeb 2, 2026
Faith L. CharlesDirector$34.3K–Nov 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ABEO short interest

Very high short interest. 29.5% of ABEO shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went up 17%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 16.88M ABEO shares were sold short, 29.5% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 778,947 shares, buying them all back would take about 21.7 trading days (days to cover).

Shares short, % of all shares

29.5%May 15Oct 3031.1%

Days to cover

21.7May 15Oct 3023.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202616.88M29.52%-2%778,94721.7
Oct 15, 202617.21M30.10%+2%1.36M12.7
Sep 30, 202616.88M29.52%+7%1.46M11.6
Sep 15, 202615.75M27.53%+4%1.31M12.0
Aug 31, 202615.16M26.51%+6%1.09M13.9
Aug 14, 202614.27M24.96%+5%2.08M6.9
Jul 31, 202613.64M23.91%+3%1.06M12.9
Jul 15, 202613.23M23.20%-3%1.60M8.3
Jun 30, 202613.68M23.98%-3%1.58M8.7
Jun 15, 202614.14M24.78%-2%860,47216.4
May 29, 202614.39M25.23%-1%877,33216.4
May 15, 202614.47M25.36%-12%1.42M10.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Abeona Therapeutics company events

Abeona Therapeutics filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Nov 9, 2026DealThe information contained above in Item 1.01 is hereby incorporated by reference into this Item 2.01. Filing
  3. Sep 15, 2026AnnouncementShared information with investors. Filing
  4. Aug 13, 2026ResultsReleased financial results. Filing
  5. Jun 12, 2026VoteReported shareholder vote results. Filing
  6. Jun 12, 2026LeadershipMichael Amoroso resigned as a member of the Board of Directors of Abeona Therapeutics Inc. effective immediately. Filing
  7. Jun 10, 2026AnnouncementShared information with investors. Filing
  8. Jun 4, 2026AnnouncementAbeona Therapeutics Inc. participated in a pre-Investigational New Drug application meeting with the U.S. Food and Drug Administration regarding ABO-701, a recently licensed radically novel engineered T-cell therapy, targeting Prostate-Specific Membrane Antigen to treat prostate cancer. Filing
  9. May 13, 2026ResultsReleased financial results. Filing
  10. Apr 7, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  11. Mar 20, 2026RulesChanged its bylaws or articles. Filing
  12. Mar 17, 2026ResultsReleased financial results. Filing
  13. Mar 9, 2026AnnouncementAbeona Therapeutics Inc. issued a press release entitled “Abeona Therapeutics ® Provides Business Update Highlighting Building Momentum in ZEVASKYN ® Commercial Launch.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Abeona Therapeutics financials

Famous investors that hold ABEO

2 of the 50 well-known investors we track reported holding ABEO in their latest 13F filing. The largest position is Israel Englander's, worth $860K.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026163,890$860K0.0%-22%
Ken Griffin · Citadel AdvisorsQ3 202616,898$88.7K0.0%-93%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named ABEO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Rubric Capital Management LP13G5.8%
Nov 16, 2026TPG GP A, LLC13G7.0%
Nov 16, 2026Rubric Capital Management LP13G5.8%
Nov 16, 2026TPG GP A, LLC13G7.0%
Nov 13, 2026Funicular Funds, LP13G/A7.5%
Nov 13, 2026Funicular Funds, LP13G/A7.5%
Nov 12, 2026Daniel Kaufman13G/A7.3%
Nov 12, 2026Daniel Kaufman13G/A7.3%
Oct 23, 2026James Russell Revocable Trust13D6.1%
Oct 23, 2026James Russell Revocable Trust13D6.1%

Questions about Abeona Therapeutics Inc. (ABEO) stock

Who owns the most ABEO stock?

The largest reported owner of Abeona Therapeutics Inc. (ABEO) is Nantahala Capital Management, LLC, with 18.0% of the company. In total, 127 funds and institutions reported holding ABEO at the end of Q2 2026, together about 78% of the shares. See the largest owners.

Are ABEO insiders buying or selling?

In the last 12 months, ABEO insiders reported 1 open-market purchase worth $34.3K and 37 sales worth $3.5M. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in ABEO?

As of Oct 30, 2026, 16.88M ABEO shares were sold short, 29.5% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 778,947 shares, buying them all back would take about 21.7 trading days (days to cover). See the history.

Which famous investors hold ABEO?

2 of the 50 well-known investors we track reported ABEO in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $860K. See all holders.

Executive pay

Abeona Therapeutics's chief executive was paid a total of $4M for the year ended Dec 31, 2025, up 14% from $3.5M the year before. In the last 12 months, Abeona Therapeutics's executives and directors bought $34.3K of stock on the open market and sold $3.5M.

Chief executive, total pay$4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.